What is OpAns?
OpAns operates at the intersection of advanced biotechnology and clinical compliance, providing specialized services that address the critical needs of payors, providers, and the justice system. Central to its value proposition is the patented amasse device, a proprietary technology that facilitates efficient micro-sampling for the detection of steroid hormones and various biomarkers. With over two decades of industry experience, the company has successfully transitioned from a niche service provider to a critical component of the diagnostic supply chain. Their focus on personalized testing and regulatory compliance positions them as a high-authority entity in the bioanalytical space, capable of navigating the rigorous demands of modern healthcare and forensic environments.
How much funding has OpAns raised?
OpAns has raised a total of $482K across 2 funding rounds:
Debt
$150K
Debt
$332K
Debt (2020): $150K with participation from PPP
Debt (2021): $332K led by PPP
Key Investors in OpAns
PPP
Public-Private Partnership
What's next for OpAns?
With the recent influx of capital, OpAns is well-positioned to accelerate its market penetration and enhance its technological footprint. The strategic deployment of these funds will likely focus on the optimization of analytical workflows and the expansion of the amasse device's application across new clinical verticals. As the company moves deeper into its late-stage lifecycle, the emphasis will shift toward operational efficiency and the scaling of its diagnostic services to meet the increasing demand for rapid, accurate, and compliant testing solutions. Investors and stakeholders will be monitoring the firm's ability to leverage this debt-based financing to drive long-term value and maintain its competitive edge in the rapidly evolving diagnostics landscape.
See full OpAns company page
